natgillin/translations-raw huggingface dataset:
The quality requirements set for the species Sorghum spp. are mainly based on the species Sorghum bicolor (L.) Moench.
Zahteve glede kakovosti za vrsto Sorghum spp. v glavnem temeljijo na vrsti Sorghum bicolor (L.) Moench.
As a result of the newly developed market for forage and biomass production the demand for other subspecies and hybrids of Sorghum spp. with smaller grain size and thinner and platter form has increased.
Zaradi novo nastalega trga za proizvodnjo krme in biomase se je povečalo povpraševanje po drugih podvrstah in hibridih Sorghum spp. z manjšo velikostjo zrn ter tanjšo in ploščatejšo obliko.
Consequently, the requirements for separate subspecies should be further developed in order to take into consideration their seed characteristics.
Zato bi bilo treba podrobneje določiti zahteve za ločene podvrste, da se upoštevajo značilnosti njihovih semen.
The species Sorghum spp. should be differentiated into Sorghum bicolor (L.) Moench, Sorghum sudanense (Piper) Stapf and hybrids thereof, and their sample sizes should be adapted to the standards set by the ISTA.
Vrsto Sorghum spp. bi bilo treba razdeliti na Sorghum bicolor (L.) Moench, Sorghum sudanense (Piper) Stapf in njihove hibride, velikosti vzorcev pa prilagoditi standardom ISTA.
Directives 66/401/EEC and 66/402/EEC should therefore be amended accordingly.
Direktivi 66/401/EGS in 66/402/EGS bi bilo treba zato ustrezno spremeniti.
The measures provided for in this Directive are in accordance with the opinion of the Standing Committee on Seeds and Propagating Material for Agriculture, Horticulture and Forestry,
Ukrepi iz te direktive so v skladu z mnenjem Stalnega odbora za semenski material za poljedelstvo, vrtnarstvo in gozdarstvo –
in Table A of Section I(2) of Annex II, concerning the entry for Galega orientalis Lam., in column 2 the number ‘60’ is replaced by the following:
V razpredelnici A oddelka I(2) Priloge II v zvezi z vnosom za Galega orientalis Lam. v stolpcu 2 se številka „60“ nadomesti z naslednjim:
‘60 (a)(b)’;
„60 (a)(b)“.
in column 1 of Annex III, the entry for ‘Poaceae (Gramineae)’ is replaced by the following:
V stolpcu 1 Priloge III se vnos za „Poaceae (Gramineae)“ nadomesti z naslednjim:
‘Poaceae (Gramineae)Article 2
„Poaceae (Gramineae)Člen 2
Amendment to Directive 66/402/EEC
Sprememba Direktive 66/402/EGS
Annex III to Directive 66/402/EEC is amended as follows:
Priloga III k Direktivi 66/402/EGS se spremeni:
the entries for Sorghum bicolor, Sorghum bicolor x Sorghum sudanense and Sorghum sudanense are replaced by the following:
Vnosa za Sorghum bicolor, Sorghum bicolor x Sorghum sudanense in Sorghum sudanense se nadomestita z naslednjim:
the following entry is inserted after the entry for Sorghum sudanense (Piper) Stapf:
Za vnosom za Sorghum sudanense (Piper) Stapf se vstavi naslednji vnos:
‘Hybrids of Sorghum bicolor (L.) Moench x Sorghum sudanense (Piper) Stapf
„Hibridi Sorghum bicolor (L.) Moench x Sorghum sudanense (Piper) Stapf
Member States shall communicate to the Commission the texts of the main provisions of national law, which they adopt in the field covered by this Directive.
Države članice Komisiji sporočijo besedila bistvenih določb nacionalne zakonodaje, sprejetih na področju, ki ga ureja ta direktiva.
The maximum lot weight may be increased to 25 tonnes if the supplier has been authorised for this purpose by the competent authority.’.
Največja masa partije se lahko poveča na 25 ton, če pristojni organ to dobavitelju odobri v ta namen.“
Commission Directive 2012/38/EU
Direktiva Komisije 2012/38/EU
amending Directive 98/8/EC of the European Parliament and of the Council to include cis-Tricos-9-ene as an active substance in Annex I thereto
o spremembi Direktive 98/8/ES Evropskega parlamenta in Sveta za vključitev cis-trikoz-9-ena kot aktivne snovi v Prilogo I k Direktivi
That list includes cis-Tricos-9-ene.
Zadevni seznam vključuje cis-trikoz-9-en.
Pursuant to Regulation (EC) No 1451/2007, cis-Tricos-9-ene has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 19, repellents and attractants, as defined in Annex V to that Directive.
Na podlagi Uredbe (ES) št. 1451/2007 je bila v skladu s členom 11(2) Direktive 98/8/ES opravljena presoja cis-trikoz-9-ena glede uporabe v 19. vrsti izdelkov (repelenti in sredstva za privabljanje (atraktanti)), kot je opredeljena v Prilogi V k navedeni direktivi.
Austria was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 11 November 2009 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.
Avstrija, ki je bila imenovana za državo članico poročevalko, je 11. novembra 2009 v skladu s členom 14(4) in (6) Uredbe (ES) št. 1451/2007 Komisiji poslala poročilo pristojnega organa in priporočilo.
In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 25 May 2012, in an assessment report.
V skladu s členom 15(4) Uredbe (ES) št. 1451/2007 so bile ugotovitve pregleda v okviru Stalnega odbora za biocidne pripravke z dne 25. maja 2012 vključene v poročilo o oceni.
It appears from the evaluations that biocidal products used as attractants and containing cis-Tricos-9-ene may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC.
Iz presoje je razvidno, da je za biocidne pripravke, ki se uporabljajo kot atraktanti in vsebujejo cis-trikoz-9-en, mogoče pričakovati, da izpolnjujejo zahteve iz člena 5 Direktive 98/8/ES.
It is therefore appropriate to include cis-Tricos-9-ene in Annex I to that Directive.
Zato je cis-trikoz-9-en primerno vključiti v Prilogo I k navedeni direktivi.
Not all potential uses and exposure scenarios have been evaluated at Union level.
Na ravni Unije niso bile ocenjene vse možnosti uporabe in primeri izpostavljenosti.
For example, outdoor use and exposure of food or feeding stuff were not assessed.
Na primer, uporaba na prostem in izpostavljenost hrane ali krme nista bili ocenjeni.
It is therefore appropriate to require that Member States assess those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment and, when granting product authorisations, ensure that appropriate measures are taken or specific conditions imposed in order to reduce the identified risks to acceptable levels.
Zato je primerno od držav članic zahtevati, da ocenijo možnosti uporabe ali primere izpostavljenosti ter tveganja za populacije ljudi in dele okolja, ki v oceni tveganja na ravni Unije niso bili reprezentativno obravnavani, ter da pri izdajanju dovoljenj za pripravke zagotovijo, da se sprejmejo ustrezni ukrepi ali določijo posebni pogoji za zmanjšanje ugotovljenih tveganj na sprejemljivo raven.
In the light of the possible indirect human exposure via consumption of food as a result of those uses represented in the assessment, it is appropriate to require, where relevant, verification of the need to set new or to amend existing maximum residue levels according to Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council [3] or Regulation (EC) No 396/2005 of the European Parliament and of the Council of 23 February 2005 on maximum residue levels of pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/EEC [4].
Zaradi možne posredne izpostavljenosti ljudi prek uživanja hrane zaradi uporab, predstavljenih v oceni, je po potrebi primerno zahtevati, da se preveri potreba po določitvi nove ali spremembi obstoječe najvišje mejne vrednosti ostankov v skladu z Uredbo (ES) št. 470/2009 Evropskega parlamenta in Sveta z dne 6. maja 2009 o določitvi postopkov Skupnosti za določitev mejnih vrednosti ostankov farmakološko aktivnih snovi v živilih živalskega izvora in razveljavitvi Uredbe Sveta (EGS) št. 2377/90 in spremembi Direktive 2001/82/ES Evropskega parlamenta in Sveta ter Uredbe (ES) št. 726/2004 Evropskega parlamenta in Sveta [3] ali Uredbo (ES) št. 396/2005 Evropskega parlamenta in Sveta z dne 23. februarja 2005 o mejnih vrednostih ostankov pesticidov v ali na hrani in krmi rastlinskega in živalskega izvora ter o spremembi Direktive Sveta 91/414/EGS [4].
The provisions of this Directive should be applied simultaneously in all Member States in order to ensure equal treatment on the Union market of biocidal products of product-type 19 containing the active substance cis-Tricos-9-ene and also to facilitate the proper operation of the biocidal products market in general.
Določbe te direktive bi bilo treba uporabljati hkrati v vseh državah članicah, da se tako na trgu Unije zagotovi enaka obravnava biocidnih pripravkov iz 19. vrste izdelkov, ki vsebujejo aktivno snov cis-trikoz-9-en, in omogoči ustrezno delovanje trga biocidnih pripravkov na splošno.
A reasonable period should be allowed to elapse before an active substance is included in Annex I to Directive 98/8/EC, in order to permit Member States and interested parties to prepare themselves to meet the new requirements entailed and to ensure that applicants who have prepared dossiers can benefit fully from the 10-year period of data protection, which, in accordance with Article 12(1)(c)(ii) of Directive 98/8/EC, starts from the date of inclusion.
Pred vključitvijo aktivne snovi v Prilogo I k Direktivi 98/8/ES bi bilo treba dovoliti ustrezno obdobje, ki bo državam članicam in zainteresiranim stranem omogočilo, da se pripravijo na izpolnjevanje novih zahtev, prijaviteljem, ki so pripravili dokumentacijo, pa zagotovilo, da lahko povsem izkoristijo desetletno obdobje za varstvo podatkov, ki se v skladu s členom 12(1)(c)(ii) Direktive 98/8/ES začne z dnem vključitve.
After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC.
Po vključitvi bi morale imeti države članice na voljo razumno dolgo obdobje za izvedbo člena 16(3) Direktive 98/8/ES.
In accordance with the Joint Political Declaration of Member States and the Commission on explanatory documents of 28 September 2011 [5], Member States have undertaken to accompany, in justified cases, the notification of their transposition measures with one or more documents explaining the relationship between the components of a directive and the corresponding parts of national transposition instruments.
Države članice so se v skladu s skupno politično deklaracijo držav članic in Komisije o obrazložitvenih dokumentih z dne 28. septembra 2011 [5] zavzele, da bodo v utemeljenih primerih uradnemu obvestilu o svojih ukrepih za prenos priložile enega ali več dokumentov, ki bodo pojasnjevali razmerje med sestavnimi deli direktive in ustreznimi deli nacionalnih instrumentov za prenos.
Member States shall adopt and publish, by 30 September 2013 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive.
Države članice najpozneje 30. septembra 2013 sprejmejo in objavijo zakone in druge predpise, potrebne za uskladitev s to direktivo.
They shall apply those provisions from 1 October 2014.
Navedene predpise uporabljajo od 1. oktobra 2014.
cis-tricos-9-ene (Muscalure)
cis-trikoz-9-en (muscalure)
cis-Tricos-9-ene; (Z)-Tricos-9-ene
cis-trikoz-9-en; (Z)-trikoz-9-en
EC No: 248-505-7
Št. ES: 248-505-7
CAS No: 27519-02-4
Št. CAS: 27519-02-4
1 October 2014
1. oktober 2014
The Union level risk assessment did not address all potential uses and exposure scenarios; certain uses and exposure scenarios, such as outdoor use and exposure of food or feed, were excluded.
V oceni tveganja na ravni Unije niso bile obravnavane vse možnosti uporabe in primeri izpostavljenosti; nekatere uporabe in primeri izpostavljenosti, kot sta uporaba na prostem in izpostavljenost hrane ali krme, so bili izključeni.
When assessing the application for authorisation of a product in accordance with Article 5 and Annex VI, Member States shall assess, where relevant for the particular product, those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment.
Kadar je za določen pripravek to potrebno, države članice pri ocenjevanju vloge za izdajo dovoljenja za pripravek v skladu s členom 5 in Prilogo VI ocenijo možnosti uporabe ali primere izpostavljenosti ter tveganja za populacije ljudi in dele okolja, ki v oceni tveganja na ravni Unije niso bili reprezentativno obravnavani.
For products containing cis-tricos-9-ene that may lead to residues in food or feed, Member States shall verify the need to set new or to amend existing maximum residue levels (MRLs) according to Regulation (EC) No 470/2009 or Regulation (EC) No 396/2005, and take any appropriate risk mitigation measures ensuring that the applicable MRLs are not exceeded.’
Za pripravke, ki vsebujejo cis-trikoz-9-en in lahko puščajo ostanke v živilih ali krmi, države članice preverijo potrebo po določitvi novih ali spremembi obstoječih najvišjih mejnih vrednosti ostankov v skladu z Uredbo (ES) št. 470/2009 ali Uredbo (ES) št. 396/2005 ter sprejmejo vse primerne ukrepe za zmanjšanje tveganja, s čimer se zagotovi, da veljavne najvišje mejne vrednosti niso presežene.“
For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm
Za izvajanje splošnih načel Priloge VI so vsebina in sklepne ugotovitve poročil o oceni na voljo na spletni strani Komisije: http://ec.europa.eu/comm/environment/biocides/index.htm.
Commission Directive 2012/39/EU
Direktiva Komisije 2012/39/EU
amending Directive 2006/17/EC as regards certain technical requirements for the testing of human tissues and cells
o spremembi Direktive 2006/17/ES o nekaterih tehničnih zahtevah za testiranje človeških tkiv in celic
Having regard to Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells [1], and in particular point (e) of the Article 28 thereof,
ob upoštevanju Direktive 2004/23/ES Evropskega parlamenta in Sveta z dne 31. marca 2004 o določitvi standardov kakovosti in varnosti darovanja, pridobivanja, testiranja, predelave, konzerviranja, shranjevanja in razdeljevanja človeških tkiv in celic [1] ter zlasti točke (e) člena 28 Direktive,
Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells [2] requires that HTLV-I antibody testing must be performed for donors living in, or originating from, high-incidence areas or with sexual partners originating from those areas or where the donor’s parents originate from those areas.
Direktiva Komisije 2006/17/ES z dne 8. februarja 2006 o izvajanju Direktive 2004/23/ES Evropskega parlamenta in Sveta o nekaterih tehničnih zahtevah za darovanje, pridobivanje in testiranje človeških tkiv in celic [2] določa, da se morajo testi za protitelesa HTLV-I opraviti na darovalcih, ki živijo na območjih z visoko pojavnostjo ali izvirajo z njih, ali darovalcih, katerih spolni partnerji ali starši izvirajo s teh območij.
This testing is required both for donors of reproductive cells, in accordance with Annex III to Directive 2006/17/EC, and for other donors, in accordance with Annex II thereof.
To testiranje se zahteva za darovalce reproduktivnih celic v skladu s Prilogo III k Direktivi 2006/17/ES, in tudi za druge darovalce v skladu s Prilogo II k Direktivi.
Recent scientific evidence provided by the European Centre for Disease Prevention and Control (ECDC) and field practice experience showed that it is very difficult, in the current state of scientific knowledge, to determine what is an HTLV-I high-incidence area.
Nedavne znanstvene ugotovitve Evropskega centra za preprečevanje in obvladovanje bolezni in izkušnje s terena so pokazale, da je glede na trenutna znanstvena dognanja zelo težko določiti, kaj je območje z visoko pojavnostjo HTLV-I.
This testing requirement is thus not implemented in a uniform manner.
Ta zahteva za testiranje se torej ne izvaja enotno.
‘Incidence’ measures the rate of occurrence of new cases of a disease or condition, while ‘prevalence’ is the proportion of a population that is affected by a particular disease at a specific time.
„Pojavnost“ pomeni pogostost pojavitve novih primerov bolezni ali stanj, „razširjenost“ pa delež prebivalstva, ki ga je v določenem trenutku prizadela določena bolezen.
In practice, data for prevalence are more available than data on incidence.
V praksi so podatki o razširjenosti dostopnejši od podatkov o pojavnosti.
In addition, prevalence is a more relevant measure than incidence when assessing the impact of a chronic disease within a community and to assess the subsequent needs.
Poleg tega je pri ocenjevanju učinka kronične bolezni v skupnosti in potreb v prihodnosti razširjenost ustreznejše merilo od pojavnosti.
It is therefore appropriate to replace references to high-incidence by references to high-prevalence in order to ensure a more consistent implementation of the HTLV-I testing requirements across the Member States.
Zato bi bilo sklicevanje na visoko pojavnost primerno nadomestiti s sklicevanjem na močno razširjenost, kar bi zagotovilo doslednejše izvajanje zahtev za testiranje HTLV-I v državah članicah.
Point 4.2 of Annex III to Directive 2006/17/EC requires that blood samples must be obtained at the time of each donation both, for partner donation (not for direct use) and for non-partner donation of reproductive cells.
V skladu s točko 4.2 Priloge III k Direktivi 2006/17/ES je treba vzorce krvi odvzeti v času vsakega darovanja reproduktivnih celic med partnerjema (ne za neposredno uporabo) in tudi pri darovanju, ki ni med partnerjema.
As far as partner donation of reproductive cells is concerned, recent scientific evidence has demonstrated that requiring testing at fixed time intervals up to a maximum of 24 months would not diminish the level of safety of the cells concerned as long as appropriate safety and quality systems are in place in tissue establishments using Assisted Reproductive Technology, in accordance with Article 16 of Directive 2004/23/EC.
V zvezi z darovanjem reproduktivnih celic med partnerjema so nedavne znanstvene ugotovitve pokazale, da zahteve za testiranje v določenih časovnih presledkih, ki trajajo največ 24 mesecev, ne bi zmanjšale ravni varnosti zadevnih celic, dokler so v skladu s členom 16 Direktive 2004/23/ES v tkivnih ustanovah, ki uporabljajo postopke asistirane reprodukcije, vzpostavljeni primerni sistemi varnosti in kakovosti.
During these time intervals, the results of the previous test carried out on the same donor can be relied upon.
Med časovnimi presledki se je mogoče zanesti na rezultate prejšnjih testov, opravljenih na istem darovalcu.
Whereas testing at the time of each donation does not improve the safety of reproductive cells donated between partners, field practice experience shows that this requirement is costly and cumbersome for both, patients and healthcare systems.
Medtem ko testiranje v času vsakega darovanja ne izboljša varnosti reproduktivnih celic, darovanih med partnerjema, izkušnje s terena kažejo, da je ta zahteva draga in naporna za paciente in sisteme zdravstvenega varstva.
In order to act in a more proportionate manner to the safety objective pursued, it is therefore appropriate to allow the Member States to require testing at fixed time intervals which they may determine up to a maximum of 24 months instead of at the time of each donation.
Za sorazmernejše ukrepanje pri doseganju cilja varnosti bi bilo zato državam članicam primerno dovoliti, da zahtevajo testiranje v določenih časovnih presledkih, ki lahko trajajo največ 24 mesecev, namesto v času vsakega darovanja.
The measures provided for in this Directive are in accordance with the opinion of the Committee set up by Article 29 of Directive 2004/23/EC,
Ukrepi, določeni v tej direktivi, so v skladu z mnenjem odbora, ustanovljenega na podlagi člena 29 Direktive 2004/23/ES –
Annexes II and III to Directive 2006/17/EC are amended in accordance with the Annex to this Directive.
Prilogi II in III k Direktivi 2006/17/ES se spremenita v skladu s Prilogo k tej direktivi.
Annexes II and III to Directive 2006/17/EC are amended as follows:
Prilogi II in III k Direktivi 2006/17/ES se spremenita:
in Annex II, point 1.2 is replaced by the following:
V Prilogi II se točka 1.2 nadomesti z naslednjim:
HTLV-I antibody testing must be performed for donors living in, or originating from, high-prevalence areas or with sexual partners originating from those areas or where the donor’s parents originate from those areas’;
Testi za protitelesa HTLV-I se opravijo na darovalcih, ki živijo na območjih z močno razširjenostjo ali izvirajo z njih, ali darovalcih, katerih spolni partnerji ali starši izvirajo s teh območij.“
point 2.4 is replaced by the following:
Točka 2.4 se nadomesti z naslednjim:
For donations other than by partners, blood samples must be obtained at the time of each donation.
Za darovanje, ki ni med partnerjema, je treba vzorce krvi odvzeti v času vsakega darovanja.
For donation by partners (not for direct use), blood samples must be obtained within three months before the first donation.
Za darovanje med partnerjema (ne za neposredno uporabo) je treba vzorce krvi odvzeti v treh mesecih pred prvim darovanjem.
For further partner donations by the same donor, further blood samples must be obtained according to national legislation, but no later than 24 months from the previous sampling.’.
Za nadaljnja darovanja med partnerjema istega darovalca je treba nadaljnje krvne vzorce odvzeti v skladu z nacionalno zakonodajo, vendar najpozneje 24 mesecev od prejšnjega odvzema vzorca.“
Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive by 17 June 2014 at the latest.
Države članice sprejmejo zakone in druge predpise, potrebne za uskladitev s to direktivo, najpozneje do 17. junija 2014 v Uradnem listu Evropske unije.
Commission Directive 2012/40/EU
Direktiva Komisije 2012/40/EU
correcting Annex I to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market
o spremembi Priloge I k Direktivi 98/8/ES Evropskega parlamenta in Sveta o dajanju biocidnih pripravkov v promet
Commission Directive 2009/91/EC of 31 July 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include disodium tetraborate as an active substance in Annex I thereto [2] defines disodium tetraborate by three CAS numbers for three different forms of the substance.
V Direktivi Komisije 2009/91/ES z dne 31. julija 2009 o spremembi Direktive 98/8/ES Evropskega parlamenta in Sveta za vključitev dinatrijevega tetraborata kot aktivne snovi v Prilogo I k Direktivi [2] je dinatrijev tetraborat opredeljen s tremi številkami CAS za tri različne oblike snovi.
The CAS numbers are based on a report submitted to the Commission by the Netherlands on 7 July 2006 and endorsed by the Standing Committee on Biocidal Products on 20 February 2009.
Številke CAS temeljijo na poročilu, ki ga je Nizozemska predložila Komisiji 7. julija 2006, 20. februarja 2009 pa ga je potrdil Stalni odbor za biocidne pripravke.